Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2662)	9/28/2001 10:51:58 AM
From: nigel bates	Read Replies (1) \| Respond to of 4974

SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 28, 2001-- Telik, Inc. (Nasdaq:TELK - news) today announced the pricing of its public offering of 4,000,000 shares of common stock at a price of $6.50 per share. All of the shares are being offered by the company. Telik has granted the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover over-allotments, if any. The offering is made through an underwriter group led by Lehman Brothers Inc., with Legg Mason Wood Walker, Inc., UBS Warburg LLC, Lazard Freres & Co. LLC and Needham & Company, Inc. co-managing the offering. A registration statement relating to these securities was filed with and has been declared effective by the U.S. Securities and Exchange Commission. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy the common stock of Telik, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the final prospectus related to the offering may be obtained from Lehman Brothers Inc., Prospectus Department, c/o ADP Financial Services, Prospectus Fulfillment, 55 Mercedes Way, Edgewood, NY 11717, telephone: 631/254-7106, fax: 631/254-7268. Telik, Inc. of South San Francisco, California, is a biopharmaceutical company working to discover, develop, and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The company's most advanced product development programs are for the treatment of cancer and diabetes....